PRESS RELEASE - Lysaker, Norway, 17th November 2025

Aidee® is in the driver's seat to win the race for the world's first clinically accepted cuff-less blood pressure monitor. After 13 years of research and many clinical trials, the company has now verified internally that its technology is ready for the last phase towards the crucial validation study required for regulatory approval. The company is now moving into the next phase and will raise up to NOK 100 million to complete the approval process.

High blood pressure (hypertension) is one of the world's greatest public health challenges and is the indirect cause of an estimated 12 million deaths each year. Only about half of those who have hypertension are aware of it, and only one in five have the condition under control.

Today, blood pressure is usually measured with an inflatable cuff around the arm. When measuring around the clock, the cuff is inflated multiple times per day, which many people find painful, stigmatizing and disruptive in everyday life.

Aidee®'s technology makes it possible to measure blood pressure continuously without a cuff. It provides a more comfortable experience and at the same time delivers far more detailed and frequent data than today's measurements. In addition, the product provides contextual information that helps doctors interpret the measurements more precisely.

The technology is based on many years of research at SINTEF Digital and gives the company a strong starting point in the international race for precise, user-friendly blood pressure monitoring.

There are several consumer products that can indicate elevated blood pressure — most recently with Apple's updates to Apple Watch. Aidee®’s product, on the other hand, targets the professional market, where the requirements for accuracy, regulatory approval and clinical validation are significantly higher. The goal for the product is to replace today's 24-hour cuff-based devices, which are recommended for the diagnosis and follow-up of high blood pressure.

Aidee® Health AS was established in 2019 as a spinoff from Datek AS in collaboration with SINTEF. The technology has been under development since 2012 at SINTEF Digital.

The development has been financed by SINTEF Venture V AS, Datek AS, Startuplab, TRK, Passesta, Stratel, SteenKap and other private investors. The project has also received significant funding from the Research Council of Norway and Innovation Norway. The project partners are SINTEF, Oslo University Hospital (Ullevål and Aker), NTNU and Sandefjord Helsepark.

The company is now proceeding with clinical validation and regulatory approval of the medical product, after which the technology will be able to be introduced to the market.

CONTACT INFO

Aidee® Health AS – Espen Westgaard, espen@aidee.io, +47 92020010

SINTEF Venture V AS – Inge Hovd Gangås, inge.hovd.gangas@sintef.no, +47 97169635

SINTEF Venture V

SINTEF Venture V's investment in Aidee® Health AS is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments.

SINTEF is one of Europe's largest research institutes with multidisciplinary expertise in science and technology. SINTEF Venture V is an early-stage investment fund focused on the commercialization of research results. The fund has a capital base of NOK 500 million provided by SINTEF, the European Investment Fund and several private institutional Norwegian investors. The European Investment Fund (EIF) is the EU's instrument for investing in equity funds in the EEA area. The investment in SINTEF Venture V, which is EIF's largest investment in Norway, has been made possible through funds from InnovFin Equity and financial instruments under the EU's Horizon 2020.

SINTEF

SINTEF is one of Europe's largest research institutes. Since 1950, we have created innovation through assignments for business and the public sector at home and abroad. SINTEF has 2200 employees from 80 nations and an annual turnover of more than four billion kroner. An important part of SINTEF's strategy is to manage intellectual property rights (IPR) in a professional manner, through the establishment of companies, sales and licensing of technology. SINTEF TTO AS is SINTEF's wholly owned commercialisation company and has corporate responsibility for driving this process together with the management of the business areas. As a tool in the process of developing new companies, SINTEF TTO manages the venture portfolio through SINTEF Venture. See sintef.no/tto

Startuplab

Startuplab is both physical incubators in Oslo and Bergen, a national accelerator program and the country's most active early-phase investor – well helped by a unique partnership with several of the country's largest companies. Our community is created by and for the country's most ambitious company builders, and Startuplab is a proud investor in Aidee®, which we believe has a very large and global potential.

Datek AS

For 25 years, we have been developing and delivering technology solutions for a more connected society. What started as deliveries within Machine to Machine (M2M) for the business market has evolved along with the digital revolution. Today, we are a key player in the Internet of Things (IoT) and build on our history, with an eye on the future.

Download press release (English and Norwegian)